Dianthus Therapeutics, Inc. (DNTH)

NASDAQHealth CareBiotechnologySnapshot 2026-11-04

$85.81+3.76%

Close 2026-11-04 · 1-day change

Investment OutlookAs of Nov 4, 2026

What could strengthen or challenge Dianthus Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

Matching fiscal periods, usable estimates and at least one analyst are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.

Price, analyst earnings & P/E reference

The EPS and P/E reference is not available for DNTH yet.

Measure / period	Management expectations	Analyst expectations

Management figures unavailable.

Current consensus figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Early GO decision for CAPTIVATE Part A maintained	Dianthus aims for an early GO decision on CAPTIVATE Part A, showing progress with a 95.5% score.	Intact	Early GO decision progress score falls below 95%	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.60

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Early GO decision for CAPTIVATE Part A maintainedDirect metric needs a verified mapping
EPS reaches at least $0.85 by June 2026Published status: Broken
Revenue decline moderates from -64% expectedDirect metric needs a verified mapping

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-37.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Dianthus Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 31, 2026

What kind of bet this is

This is a speculative growth investment in a clinical-stage healthcare company, not an established earnings compounder. The thesis is in a watch state: management has met key trial milestones, but the recent signal has turned mixed and business risk remains elevated.

What's priced into Dianthus Therapeutics, Inc.

The valuation model indicates DNTH trades at a premium to peers, while the expectations gap is meaningful and driven by the potential value of future programs. Confidence in that valuation read is low, and the evidence does not support a firm conclusion about how much future success is already reflected.

What the fundamentals likely do

Near term, financial performance remains weak and the company is loss-making, despite earnings beats in May and August after a miss in March. Over the multi-year view, clinical progress is the main fundamental driver: EMERGE began on schedule, while CAPTIVATE Part B and DNTH212 remain important upcoming milestones. A guidance cut or a weaker economic backdrop could add pressure, and the industry has a high rate of misses.

What Dianthus Therapeutics, Inc. hinges on

The thesis depends on management delivering top-line guidance for CAPTIVATE Part B by year-end 2026 and advancing DNTH212 studies as planned. EMERGE’s top-line results are expected in the second half of 2028, so its contribution to the multi-year view depends on later clinical evidence. Healthcare sector momentum could help sentiment near term, while guidance cuts or rising recession concerns are key unfavorable scenarios.

Bottom line

For the next 1 to 3 years, DNTH’s long-term thesis rests on clinical execution rather than current financial strength. Progress is visible, but elevated risk, weak results, and low-confidence valuation evidence leave the outlook uncertain. Not investment advice.

Development preview · refreshed Nov 5, 2026Open Living FV detail

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.48	$1,819,273	9 / 9
2026-07-25	$-4.65	$1,585,330	9 / 12
2026-07-26	$-4.65	$1,585,330	9 / 12
2026-07-27	$-4.65	$1,585,330	9 / 12
2026-07-28	$-4.65	$1,585,330	9 / 12
2026-07-29	$-4.48	$1,819,273	9 / 9
2026-07-30	$-4.65	$1,585,330	9 / 12
2026-07-31	$-4.65	$1,585,330	9 / 12
2026-08-01	$-4.48	$1,819,273	9 / 9
2026-08-02	$-4.65	$1,585,330	9 / 12
2026-08-03	$-4.65	$1,585,330	9 / 12
2026-08-04	$-4.65	$1,585,330	9 / 12
2026-08-05	$-4.48	$1,819,273	9 / 9
2026-08-06	$-4.48	$1,819,273	9 / 9
2026-08-07	$-4.63	$2,035,917	9 / 8
2026-08-08	$-4.65	$2,059,500	9 / 10
2026-08-09	$-4.65	$2,059,500	9 / 10
2026-08-10	$-4.65	$2,059,500	9 / 10
2026-08-11	$-4.74	$2,059,500	9 / 10
2026-08-12	$-4.74	$1,716,250	9 / 12
2026-08-13	$-4.63	$2,035,917	9 / 8
2026-08-14	$-4.63	$2,035,917	9 / 8
2026-08-15	$-4.63	$2,035,917	9 / 8
2026-08-16	$-4.63	$2,035,917	9 / 8
2026-08-17	$-4.63	$2,035,917	9 / 8
2026-08-18	$-4.63	$2,035,917	9 / 8
2026-08-19	$-4.63	$2,035,917	9 / 8
2026-08-20	$-4.65	$2,035,917	9 / 9
2026-08-21	$-4.65	$2,035,917	9 / 9
2026-08-22	$-4.65	$2,035,917	9 / 9
2026-08-23	$-4.65	$2,035,917	9 / 9
2026-08-24	$-4.65	$2,035,917	9 / 9
2026-08-25	$-4.65	$2,035,917	9 / 9
2026-08-26	$-4.65	$2,035,917	9 / 9
2026-08-27	$-4.65	$2,035,917	9 / 9
2026-08-28	$-4.65	$2,035,917	9 / 9
2026-08-29	$-4.65	$2,035,917	9 / 9
2026-08-30	$-4.65	$2,035,917	9 / 9
2026-08-31	$-4.65	$2,035,917	9 / 9
2026-09-01	$-4.65	$2,035,917	9 / 9
2026-09-02	$-4.65	$2,035,917	9 / 9
2026-09-03	$-4.65	$2,035,917	9 / 9
2026-09-04	$-4.65	$2,035,917	9 / 9
2026-09-05	$-4.65	$2,035,917	9 / 9
2026-09-06	$-4.57	$2,029,766	10 / 9
2026-09-07	$-4.57	$2,029,766	10 / 9
2026-09-08	$-4.57	$2,029,766	10 / 9
2026-09-09	$-4.57	$2,029,766	10 / 9
2026-09-10	$-4.57	$2,029,766	10 / 9
2026-09-11	$-4.57	$2,029,766	10 / 9
2026-09-12	$-4.57	$2,029,766	10 / 9
2026-09-13	$-4.57	$2,027,639	10 / 10
2026-09-14	$-4.57	$2,027,639	10 / 10
2026-09-15	$-4.57	$2,027,639	10 / 10
2026-09-16	$-4.57	$2,027,639	11 / 10
2026-09-17	$-4.57	$2,027,639	11 / 10
2026-09-18	$-4.57	$2,027,639	11 / 10
2026-09-19	$-4.57	$2,027,639	11 / 10
2026-09-20	$-4.57	$2,027,639	11 / 10
2026-09-21	$-4.57	$2,027,639	11 / 10
2026-09-22	$-4.57	$2,027,639	11 / 10
2026-09-23	$-4.57	$2,027,639	11 / 10
2026-09-24	$-4.57	$2,027,639	11 / 10
2026-09-25	$-4.57	$2,027,639	11 / 10
2026-09-26	$-4.57	$2,027,639	11 / 10
2026-09-27	$-4.57	$2,027,639	11 / 10
2026-09-28	$-4.57	$2,027,639	11 / 10
2026-09-29	$-4.57	$2,027,639	11 / 10
2026-09-30	$-4.57	$2,027,639	11 / 10
2026-10-01	$-4.57	$2,027,639	11 / 10
2026-10-02	$-4.57	$2,027,639	11 / 10
2026-10-03	$-4.57	$2,027,639	11 / 10
2026-10-04	$-4.57	$2,027,639	11 / 10
2026-10-05	$-4.57	$2,027,639	11 / 10
2026-10-06	$-4.57	$2,027,639	11 / 10
2026-10-07	$-4.57	$2,027,639	11 / 10
2026-10-08	$-4.57	$2,027,639	11 / 10
2026-10-09	$-4.57	$2,027,639	11 / 10
2026-10-10	$-4.57	$2,027,639	11 / 10
2026-10-11	$-4.57	$2,027,639	11 / 10
2026-10-12	$-4.57	$2,027,639	11 / 10
2026-10-13	$-4.57	$2,027,639	11 / 10
2026-10-14	$-4.57	$2,027,639	11 / 10
2026-10-15	$-4.57	$2,027,639	11 / 10
2026-10-16	$-4.57	$2,027,639	11 / 10
2026-10-17	$-4.57	$2,027,639	11 / 10
2026-10-18	$-4.57	$2,027,639	11 / 10
2026-10-19	$-4.57	$2,027,639	11 / 10
2026-10-20	$-4.57	$2,027,639	11 / 10
2026-10-21	$-4.57	$2,027,639	11 / 10
2026-10-22	$-4.57	$2,027,639	11 / 10
2026-10-23	$-4.57	$2,027,639	11 / 10
2026-10-24	$-4.57	$2,027,639	11 / 10
2026-10-25	$-4.57	$2,027,639	11 / 10
2026-10-26	$-4.57	$2,027,639	11 / 10
2026-10-27	$-4.57	$2,027,639	11 / 10
2026-10-28	$-4.60	$2,059,130	11 / 11
2026-10-29	$-4.60	$2,059,130	11 / 11
2026-10-30	$-4.60	$2,059,130	11 / 11
2026-10-31	$-4.60	$2,059,130	11 / 11
2026-11-01	$-4.60	$2,059,130	11 / 11
2026-11-02	$-4.60	$2,059,130	11 / 11
2026-11-03	$-4.60	$2,059,130	11 / 11
2026-11-04	$-4.60	$2,059,130	11 / 11

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-06-01	15	0	0
2026-07-01	15	0	0
2026-08-01	15	0	0
2026-09-01	17	0	0
2026-10-01	18	0	0
2026-11-01	18	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 18 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Oct 6–Nov 4 · 1 recorded

Dianthus Therapeutics, Inc. (DNTH) Outlook: What's Priced In | QuarterlyIQ

What could strengthen or challenge Dianthus Therapeutics, Inc.’s outlook?

Price, analyst earnings & P/E reference

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

Dianthus Therapeutics, Inc. outlook in detail

What kind of bet this is

What's priced into Dianthus Therapeutics, Inc.

What the fundamentals likely do

What Dianthus Therapeutics, Inc. hinges on

Bottom line

Analyst view

Price-target changes

Bottom line